Nothing surprises me in this report. It is as expected i.e. cash...

Nothing surprises me in this report. It is as expected i.e. cash is being used to build the generic pipeline. Good to see a little bit of growth on the Evamist and Lenzetto. The real value will come when they commercialise the generic pipeline and when sales start. At the moment, I guess they will be waiting for FDA approval on the 3 products submitted. Once we receive approval i'm sure we will see a licencing agreement soon after.

18m of cash left, looks like this will be enough for another year and a bit. Hopefully sales begins before then and we do not need a capital raise.